Response to: Letter to Editor Regarding “Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study”

• A. David Burden

Affiliations

A. David Burden

School of Infection and Immunity, University of Glasgow